Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were ...

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results , but sales were flat year on year at $3.75 billion. Its ...

Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.67%, the company showcases ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 17 ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...

Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you ...

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, ...

Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected ...

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 ...